UNIV UZ Gent
Welcome,         Profile    Billing    Logout  
 28 Trials 
53 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brusselle, Guy
PREDICTUMAB, NCT03476109 / 2017-002473-19: Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.

Recruiting
4
100
Europe
Randomisation to omalizumab, Active-controlled, Randomisation to mepolizumab
Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital, Ghent, University of Liege, CHU de Charleroi, Erasme University Hospital, Centre Hospitalier Universitaire Dinant Godinne - UCL Namur, Universitair Ziekenhuis Brussel, Brugmann University Hospital, Grand Hôpital de Charleroi, AZ Delta, Centre Hospitalier Universitaire Saint Pierre, KU Leuven
Severe Asthma
12/23
12/24
Geboes, Karen
SAUNA, NCT05701241: Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Recruiting
4
270
Europe
Somatostatin analog, lanreotide, octreotide, sandostatin, somatuline
University Hospital, Antwerp, Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre
Gastroenteropancreatic Neuroendocrine Tumor
04/29
04/34
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
FAPIDO, NCT06782412: Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

Recruiting
2/3
109
Europe
[18F]AlF-FAPI-74 PET/CT
KU Leuven, University Hospital, Ghent, University Hospital, Antwerp, Universitaire Ziekenhuizen KU Leuven, Kom Op Tegen Kanker
Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP, Oncology, Oncologic Disorders
12/27
12/27
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
REGINA, NCT04503694 / 2020-000876-40: Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Recruiting
2
72
Europe
Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy, Surgery, Non-operative Management
Jules Bordet Institute
Rectal Cancer Stage II, Rectal Cancer Stage III
01/26
12/30
NALPAC, NCT05472259 / 2020-003889-39: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC

Recruiting
2
134
Europe
Nanoliposomal irinotecan, Onyvide, 5 FU, Fluorouracil, Leucovorin, Folinate, Elvorine, Oxaliplatin
Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels
Metastatic Pancreatic Ductal Adenocarcinoma
12/26
12/27
STEREOPAC, NCT05083247: Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Recruiting
2
256
Europe
mFOLFIRINOX or Gemcitabine nab-paclitaxel, mFFX or Gem/Nab-p, Isotoxic High-Dose (iHD)-SBRT, Surgery
Erasme University Hospital, Jules Bordet Institute, Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels
Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
12/27
12/30
OPTIMIZE-1, NCT04888312 / 2020-005182-14: Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients

Active, not recruiting
1/2
94
Europe
CD40 agonist mitazalimab in combination with chemotherapy, ADC-1013, JNJ-64457107
Alligator Bioscience AB, Theradex, BC Platforms
Metastatic Pancreatic Ductal Adenocarcinoma
01/24
06/26
NCT05704530: Liquid Biopsies in Esophageal Cancer

Recruiting
N/A
248
Europe
Blood sample
Universitaire Ziekenhuizen KU Leuven, Kom Op Tegen Kanker
Esophageal Cancer
09/25
12/26
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
SHAPERS, NCT06052332: Efficacy and Safety of SCRT Versus TNT in Older Patients With Locally Advanced Rectal Cancer

Recruiting
N/A
230
Europe
Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision, Total neoadjuvant therapy
Jules Bordet Institute
Locally Advanced Rectal Cancer, Older People
12/29
12/33
Lapauw, Bruno
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
ONZ-2023-0185, NCT06269159: The Power of 24-hour: Co-designing Intervention Components

Recruiting
N/A
210
Europe
Concept mapping: brainstorm, Concept mapping: clustering and rating
University Hospital, Ghent
Overweight and Obesity
03/25
03/25
SVT-DNP, NCT06519942: Muscle and Bone in Patients with Diabetes Mellitus and Neuropathy

Recruiting
N/A
145
Europe
Blood sampling, Electromyoneurography (EMNG), Muscle biopsy, Quantitative peripheral computed tomography (qPCT), Mechanography, Electrocardiography (ECG), Questionnaires, Anthropometry
University Hospital, Ghent, University Ghent
Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy, Sarcopenia
11/25
11/25
24h-MBs_T1D, NCT06425640: 24-hour Movement Behaviors in Adults With Type 1 Diabetes

Recruiting
N/A
150
Europe
24-hour movement behavior
University Hospital, Ghent, University Ghent
Diabetes Mellitus, Type 1
12/25
12/25
OwOb_24hmb, NCT05367570: 24-hour Movement Behaviors Among Normal Weight, Overweight and Obese Adults

Completed
N/A
250
Europe
Cross-sectional observational study
University Hospital, Ghent, University Ghent
Overweight and Obesity
12/22
10/23
NCT04993482: 24-hour Movement Behaviors Among Type 2 Diabetes Mellitus Patients

Recruiting
N/A
248
Europe
No intervention
University Hospital, Ghent, University Ghent
Diabetes Mellitus, Type 2
12/26
12/26
PPPIL, NCT06810635: Polyphenol Metabotypes in People with Diabetes Type 2

Not yet recruiting
N/A
100
Europe
Oral Polyphenol Challenge Test / PPPIL, fasting blood sample, Fasting urine collection, 24 hours urine collection, Questionnaires, Stool collection, Transit time determination
University Hospital, Ghent, University Ghent, University of Parma, Universiteit Antwerpen
Type 2 Diabetes Mellitus (T2DM)
11/28
12/28
NCT05777330: Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes

Recruiting
N/A
75
Europe
Oral glucose tolerance test (OGTT), OGTT, Hyperglycemic clamp test, clamp, Continuous glucose monitoring, Dexcom G6, CGM
Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Juvenile Diabetes Research Foundation
Type1 Diabetes Mellitus
04/26
04/27
Rottey, Sylvie
NCT03810872: An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Recruiting
2
87
Europe
Afatinib, Paclitaxel
AZ-VUB
Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation
12/20
12/22
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
BT5528-100, NCT04180371 / 2019-003653-29: Study in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Recruiting
1/2
288
Europe, US, RoW
BT5528, Nivolumab, Opdivo
BicycleTx Limited
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
10/25
10/25
IMAG1NE, NCT05430555: A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors

Terminated
1/2
23
Europe
Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
T-knife GmbH
Advanced Solid Tumors
01/24
01/24
NCT06667960: A Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
155
Europe
JK06
Salubris Biotherapeutics Inc
Solid Tumor
04/28
08/28
NCT05159388: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Active, not recruiting
1/2
45
Europe, US, RoW
PRS-344/S095012
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Solid Tumor
07/25
07/25
NCT05620134 / 2022-000339-21: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting
1/2
263
Europe
JK08, Pembrolizumab, Lenvatinib Pill
Salubris Biotherapeutics Inc, Salubris Biotherapeutics, Inc.
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Melanoma, Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Urothelial Carcinoma, Squamous Cell Carcinoma of Head and Neck, Luminal Breast Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Gastric Adenocarcinoma, GastroEsophageal Cancer, Squamous Cell Carcinoma Skin, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Adenocarcinoma, Epithelial Ovarian Cancer, Thyroid Cancer
10/25
02/26
MCLA-145-CL01, NCT03922204: A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Completed
1
72
Europe, US
MCLA-145, bispecific, Pembrolizumab (Keytruda)
Merus N.V., Incyte Corporation
Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
11/24
11/24
NCT03990233: A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Checkmark From trial in combination with BI 754091 for solid tumors
Jun 2021 - Jun 2021: From trial in combination with BI 754091 for solid tumors
Active, not recruiting
1
116
Europe
BI 765063, OSE-172, BI 754091
OSE Immunotherapeutics, Boehringer Ingelheim
Solid Tumor, Adult
04/23
12/25
KEYNOTE-B79, NCT04991948: Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting
1
34
Europe, US
CYAD-101, FOLFOX, Pembrolizumab
Celyad Oncology SA, Merck Sharp & Dohme Corp.
Unresectable Metastatic Colorectal Cancer
08/23
05/38
NCT05117177: New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer

Completed
1
57
Europe
Inupadenant, EOS100850
iTeos Therapeutics, iTeos Belgium SA
Solid Tumor, Adult
05/24
05/24
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours

Recruiting
1
25
Europe
DO-2
DeuterOncology
Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer
12/25
12/26
CDR404-001, NCT06402201: First in Human Study of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

Recruiting
1
42
Europe, US
CDR404
CDR-Life AG
Select Advanced Solid Tumors
06/26
12/27
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
NCT04641676: A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center

Recruiting
N/A
1000
Europe
NGS testing
The Belgian Society of Medical Oncology, Foundation Medicine, Sciensano, Roche Pharma AG
Metastatic Cancer, Local Tumor Invasion
09/22
12/22
REAL-V, NCT05033158: The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.

Completed
N/A
402
Europe
Blood sampling
University Hospital, Antwerp, KomOpTegenKanker (non-profit organization)
Cancer
12/22
06/23
BALLETT, NCT05058937: A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre

Recruiting
N/A
936
Europe
Comprehensive genomic profiling
The Belgian Society of Medical Oncology, Illumina, Inc., OncoDNA, PierianDx
Solid Tumor, Metastatic Cancer
05/23
05/26
NCT03873103: The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment

Recruiting
N/A
1000
Europe
The Belgian Society of Medical Oncology
Metastatic Cancer
12/23
12/23
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
Smith, Vanessa
NCT04464434 / 2019-004718-32: Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

Recruiting
4
50
Europe
Upfront autologous HSCT
UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, Boehringer Ingelheim, Miltenyi Biotec, Inc.
Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse, Autologous Stem Cell Transplantation, Cyclophosphamide, Mycophenolate Mofetil, Treatment Strategy
10/27
10/30
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting
3
225
RoW
Belimumab
GlaxoSmithKline, ICON plc
Bronchial Diseases
07/28
01/30
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
07/27
07/27
NCT03015896: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Active, not recruiting
1/2
36
US
Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
David Bond, MD, Bristol-Myers Squibb
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
12/24
12/24
NCT03501576: Evaluation of Human Immune Responses Vaccination in Patients with Lymphoma

Recruiting
N/A
200
US
Inactivated Influenza Vaccine, Fluzone Quadrivalent, Fluzone Quadrivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine, Flu Vaccine
Emory University
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
05/26
05/26
Hindryckx, Pieter
POELH-II, NCT05678218: Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma

Recruiting
N/A
200
Europe
Endoscopic Ultrasound registration
Erasmus Medical Center
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Common Bile Duct Neoplasms, Cholangiocarcinoma, Adenocarcinoma
02/25
02/26
LABOR, NCT05640947: Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass

Recruiting
N/A
20
Europe
The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System, LAMS
University Hospital, Ghent
Hypoglycemia, Gastric Outlet Obstruction, Steatohepatitis, Parenteral Support, Gastric Bypass
10/25
02/26

Download Options